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Abstract
Background: The ILEP Nerve Function Impairment in Reaction (INFIR) is a cohort study designed to identify predictors of
reactions and nerve function impairment in leprosy. The aim was to study correlations between clinical and histological
diagnosis of reactions.
Methodology/Principal Findings: Three hundred and three newly diagnosed patients with World Health Organization
multibacillary (MB) leprosy from two centres in India were enrolled in the study. Skin biopsies taken at enrolment were
assessed using a standardised proforma to collect data on the histological diagnosis of leprosy, leprosy reactions and the
certainty level of the diagnosis. The pathologist diagnosed definite or probable Type 1 Reactions (T1R) in 113 of 265
biopsies from patients at risk of developing reactions whereas clinicians diagnosed skin only reactions in 39 patients and 19
with skin and nerve involvement. Patients with Borderline Tuberculoid (BT) leprosy had a clinical diagnosis rate of reactions
of 43% and a histological diagnosis rate of 61%; for patients with Borderline Lepromatous (BL) leprosy the clinical and
histological diagnosis rates were 53.7% and 46.2% respectively. The sensitivity and specificity of clinical diagnosis for T1R
was 53.1% and 61.9% for BT patients and 61.1% and 71.0% for BL patients. Erythema Nodosum Leprosum (ENL) was
diagnosed clinically in two patients but histologically in 13 patients. The Ridley-Jopling classification of patients (n = 303)
was 42.8% BT, 27.4% BL, 9.4% Lepromatous Leprosy (LL), 13.0% Indeterminate and 7.4% with non-specific inflammation.
This data shows that MB classification is very heterogeneous and encompasses patients with no detectable bacteria and
high immunological activity through to patients with high bacterial loads.
Conclusions/Significance: Leprosy reactions may be under-diagnosed by clinicians and increasing biopsy rates would help
in the diagnosis of reactions. Future studies should look at sub-clinical T1R and ENL and whether they have impact on
clinical outcomes.
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Introduction
Diagnosing leprosy and the immunological reactions that
complicate this disease is not always straightforward. Leprosy skin
lesions can have a very variable appearance and the presence of
inflammation which is associated with immune reactions is not
always obvious. The INFIR cohort study was set up in North India
in 2000 to study risk factors for leprosy reactions in a cohort of
newly diagnosed patients with multibacillary (MB) leprosy.
Patients with definite clinical evidence of MB leprosy were
recruited to the cohort. All patients had a skin biopsy on
recruitment. Previous publications relating to this cohort have
reported on clinical and neurophysiological aspects of the study.
Important clinical findings included the observations that there
was a high level of nerve damage in these patients and that new
nerve damage and clinical reactions were detectable in 28% of
patients at recruitment. [1] The serological studies showed that
LAM IgG1 antibody levels were significantly elevated in patients
with skin reactions and nerve function impairment (NFI). [2] The
immuno-histological studies in skin biopsies have shown a
significant association between the presence of three cytokine
proteins, TNF-a, iNOS and TGF-b, and Type 1 Reactions (T1R)
in skin and nerve damage. [3] This paper reports on the
correlation between the clinical and the histological findings.
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The clinical manifestations of leprosy are determined by the
immune response of the patient to Mycobacterium leprae. There is a
spectrum of immune responses. Patients with tuberculoid leprosy
(TT) have well developed cell mediated immunity and localised skin
or nerve lesions, whilst patients at the other end of the spectrum
have lepromatous leprosy (LL) which is associated with absent cell
mediated immunity, mycobacterial proliferation and numerous skin
and nerve lesions. Between these two extremes are the borderline
types of leprosy in which patients have decreasing levels of cell
mediated immunity and increasing numbers of lesions as they move
from borderline tuberculoid (BT) to borderline lepromatous (BL).
Patients are assigned a Ridley-Jopling classification on the basis of
the morphology, type and number of skin lesions, and nerve
involvement, supplemented by the bacterial index (BI) [4] and
histological examination of the skin lesion wherever possible. The
Ridley-Jopling types are Tuberculoid (TT), Borderline Tuberculoid
(BT), Borderline Borderline (BB), Borderline Lepromatous (BL),
Lepromatous Lepromatous (LL), Pure Neural (PN) and Indetermi-
nate (I). The Ridley-Jopling classification links immune status and
clinical manifestations. Patients with borderline leprosy are
immunologically unstable and at risk of developing leprosy reactions
and NFI. The Leprosy Unit at the World Health Organization
(WHO) has developed a simpler classification for use in the field and
for assigning patients to treatment regimens. Patients are classified
on the number of skin and nerve lesions and skin smear positivity/
negativity. Patients with up to five skin lesions and/or one nerve
involved and smear negativity are classified as having paucibacillary
leprosy (PB) and are treated with six months of PB multi-drug
therapy (MDT) and patients with more than five skin lesions and/or
more than one nerve involved and/or smear positivity are classified
as having multi-bacillary (MB) leprosy and receive 12 months of MB
MDT. [5] In referral centres both classification systems may be
used. Previous studies comparing clinical and histological diagnoses
have found variability between the two ways of classifying patients.
Moorthy et al [6] assessed 372 skin biopsies in patients in India and
found agreement between the clinical and histological diagnoses in
only 62.6% of cases. Pardillo et al [7] in a study in the Philippines
found substantial under-diagnosis of BB/BL and BL disease with
38% of these patients having fewer than five lesions and so being
classified as PB. In the INFIR cohort study patients were recruited
using the WHO classification but then assigned a Ridley-Jopling
classification using clinical criteria and then had a histological
classification made from the skin biopsy. This allows us to compare
the clinical and histological classifications. Classification of leprosy
patients is important because if under-diagnosis of MB patients
occurs, then patients with a significant bacterial load will be under-
treated and be at risk of relapse. Conversely, patients who have low
bacterial loads but more than five lesions will be classified as having
MB type leprosy and will be over-treated.
T1R are delayed hypersensitivity reactions and are clinically
important because acute peripheral nerve damage occurs during these
episodes. T1R are clinically defined by the presence of new erythema
in skin lesions and new loss of nerve function in peripheral nerves.
Histologically, oedema and inflammation are seen in leprosy
granulomas in skin and nerve biopsies. [8,9] The clinical definition
of Type 1 and Type 2 Reactions has developed by consensus with little
testing of the accuracy of clinical diagnosis of T1R. A previous study in
India compared the diagnostic rates for T1R by clinicians and
histopathologists [10] and showed that clinicians had a higher rate of
diagnosing reactions than histopathologists. In that study the clinical
diagnosis of a T1R was accompanied by histological changes in 60%
cases. The structure of the INFIR cohort with all patients having a
biopsy taken at baseline enables us to examine the diagnoses of T1R
clinically and histologically and to calculate sensitivity and specificity
rates for these different diagnostic tools. We predicted that the
clinicians would have a higher rate of diagnosis of T1R than the
histopathologist. We also predicted that there would be reactions
diagnosed on histological examination that had not been apparent
clinically.
Erythema Nodosum Leprosum (ENL) is an immune-mediated
common complication of LL, occurring in about 50% of patients
with LL, and presenting with skin lesions (red, painful and tender
subcutaneous lesions), fever and systemic inflammation that may
affect the nerves, eyes, joints, testes and lymph nodes. [11,12] The
diagnosis of ENL has also evolved by consensus with different case
definitions being used. [13] The case definition for ENL in the
INFIR cohort was based on detecting skin lesions and systemic
signs/symptoms of inflammation in patients with BL/LL classifi-
cation. ENL is diagnosed histologically when a vasculitis with
neutrophil polymorph cells infiltrating the lesions are present. [8]
A study in Pakistan comparing the clinical and histological
diagnosis of ENL found that 36% of patients with clinically
diagnosed ENL did not have the typical cell infiltrates associated
with vasculitis in their skin biopsies. [14] Thus, there are also
discrepancies between clinical and histological diagnoses of ENL.
In the INFIR cohort study we tested the correlation between the
clinical and histological diagnoses of ENL at entry into the cohort.
The INFIR cohort study allowed us to compare the diagnosis of
leprosy and both types of reaction in a cohort of newly diagnosed
patients. We report here on the following comparisons:
1. The clinical and histological leprosy diagnoses in cohort;
2. The clinical and histological diagnoses of T1R;
3. The clinical and histological diagnoses of ENL.
Materials and Methods
Design
This was a cohort study of 303 newly registered MB patients.
The patients were followed up monthly for one year and every
second month during the second year.
Author Summary
Leprosy affects skin and peripheral nerves. Although we
have antibiotics to treat the mycobacterial infection, the
accompanying inflammation is a major part of the disease
process. This can worsen after starting antibacterial
treatment with episodes of immune mediated inflamma-
tion, so called reactions. These are associated with
worsening of nerve damage. However, diagnosing these
reactions is not straightforward. They can be diagnosed
clinically by examination or by microscopic examination of
the skin biopsies. We studied a cohort of 303 newly
diagnosed leprosy patients in India and compared the
diagnosis rates by clinical examination and microscopy
and found that the microscopic diagnosis has higher rates
of diagnosis for both types of reaction. This suggests that
clinicians and pathologists have different thresholds for
diagnosing reactions. More work is needed to optimise
both clinical and pathological diagnosis. In this cohort 43%
of patients had Borderline Tuberculoid leprosy, an immu-
nologically active type, and 20% of the biopsies showed
only minimal inflammation, perhaps these patients had
very early disease or self-healing. The public health
implication of this work is that leprosy centres need to
be supported by pathologists to help with the clinical
management of difficult cases.
Leprosy Diagnoses: Clinical and Histological
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Location
Recruitment of subjects took place in The Leprosy Mission
(TLM) hospitals in Naini and Faizabad, specialist leprosy referral
centres in Uttar Pradesh, India. The histopathological analysis was
done at the LEPRA Society Blue Peter Research Centre in
Hyderabad, Andhra Pradesh.
Study population
The study population comprised newly registered MB patients
requiring a full course of MDT. A detailed description of the study
design methods, clinical definitions, documentation and the status
of the cohort at baseline have been published. [1,15]
Classification process
Patients were initially classified by the Ridley-Jopling scale
clinically before the local skin smear result was available. When
the histological diagnosis became available all the classification
diagnoses were reviewed together with slit skin smear data and
reconciled to give a final diagnosis which was then used for
subsequent analysis. For the Ridley-Jopling classification the
histological diagnosis took precedence over the clinical classifica-
tion so that a patient classified clinically as BT but with BL
histology would have a final BL classification.
Clinical case definitions of reactions
Type 1 or Reversal Reaction. T1R was diagnosed when a
patient had erythema and oedema of skin lesions. This may have
been accompanied by neuritis and oedema of the hands, feet and
face. A patient could have a skin reaction only, or a nerve reaction
only, or a skin and nerve reaction.
Erythema Nodosum Leprosum. ENL was diagnosed when
a patient had crops of tender subcutaneous skin lesions. There may
have been accompanying neuritis, iritis, arthritis, orchitis,
dactylitis, lymphadenopathy, oedema and fever.
Database
All the data obtained in the study, including the clinical,
neurophysiological, serological and histopathological data, were
entered on computer locally and subsequently merged into a single
Microsoft Access database.
Skin biopsies
All patients had an elliptical incision skin biopsy taken from
an active skin lesion at enrolment. If the patient developed a
Type 1 or Type 2 reaction a second skin biopsy was taken from
a typical active lesion. The biopsies were split in half, one
portion being fixed in 10% buffered Formalin and the other
snap frozen in liquid nitrogen and then transported to the Blue
Peter Research Centre at Hyderabad for processing and
analysis. The skin biopsies were processed and embedded in
paraffin and serially sectioned in the saggital plane at 5 mm
thickness on a Leica microtome. Sections were stained with
Haematoxylin and Eosin stain (H & E stain) to study
morphology, and modified Fite Faraco stain to identify acid
fast bacilli (AFB). AFB was graded according to Ridley scale of 0
to 6+ as Bacillary Index of Granuloma (BIG). The biopsy
assessments were done using a standardised set of definitions for
histological features and recorded on a proforma. A single
pathologist (SS) reviewed the H & E and Fite stained sections
and assessed the diagnosis of leprosy, assigned each case a
Ridley-Jopling classification and assessed the presence of leprosy
reaction.
Diagnosis of leprosy
This was confirmed when evidence of nerve inflammation and/
or AFB were seen and a granulomatous inflammation consistent
with leprosy was present. [4] The following morphological features
were assessed on all sections:
1. Cellular infiltrate/granuloma. The assessment of the
cellular infiltrate consisted of identifying granuloma formation,
type, population and maturity of the cells making up the
granuloma and the fraction of the dermis occupied by the
infiltrate (interpreted as granuloma fraction).
2. Oedema. This was present in dilated vascular channels
(capillaries and lymphatics), causing splaying out of the dermal
collagen. Extra cellular oedema was present when wide separation
of cellular infiltrate was present and intracellular oedema when
ballooning of individual cells was seen.
3. Nerve inflammation. This was graded as perineural
inflammation when the inflammatory cells were present around
the nerve and intraneural inflammation when the inflammatory
cells were found inside a nerve.
4. Necrosis. This was reported as present when caseous
necrotic foci and apoptotic cells were seen in the infiltrate.
5. Bacterial index of granuloma. This was graded from 0
to 6+ based on Ridley’s scale.
6. Ridley-Jopling classification. This was used in the
diagnosis of leprosy patients.
Lepromatous leprosy (LL): When macrophage and foam cell
collections present with numerous bacilli interspersed with sparse
number of lymphocytes.
Borderline lepromatous (BL) leprosy: When there were macro-
phage granulomas, numerous lymphocytes and moderate numbers
of bacilli.
Borderline tuberculoid (BT) leprosy: When lympho-epithelioid
granuloma presents with occasional Langhans giant cells.
Tuberculoid leprosy (TT): When immature epithelioid cells are
present together with Langhans giant cells and numerous
lymphocytes.
Indeterminate leprosy: When some nerve inflammation is seen
with rare AFB and an absence of clear epithelioid or macrophage
granulomas.
Non-specific inflammation: Used as a diagnostic category when
inflammation was present without the specific features for leprosy,
notably neural inflammation and AFB.
Type 1 Reaction (T1R): When at least two of the following
features were present: granulomas with extra and intracellular
oedema, dilated vascular channels, separation of dermal collagen,
evidence of an intense delayed-type hypersensitivity response with
acute damage to dermal nerves and granuloma. [10]
ENL reaction: When a polymorphonuclear neutrophilic infil-
trate on the background of a macrophage granuloma accompa-
nied by oedema and often with evidence of vasculitis and/or
panniculitis was seen. [9]
Validation of histological diagnosis
A purposely selected sample of 66 slides was sent to a second
pathologist who used the same scoring system for diagnosis of
leprosy and reactions. The selection covered the full range of
leprosy types and reactions. The paired assessments made by SS
and by an independent assessor blinded to the assessment by SS
were compared. There was perfect or good agreement on the
Ridley-Jopling classification in all 51 biopsies (this excludes
biopsies that showed non-specific inflammation). For the BI
assessment the Kappa was 0.5 and for the granuloma fraction
assessment the Kappa was 0.6 indicating good agreement. SS
diagnosed T1R in 20/66 biopsies and MJ in 11/66. There were
Leprosy Diagnoses: Clinical and Histological
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four T1R diagnosed by MJ but not SS and 13 diagnosed by SS but
not MJ. Comparing the ENL diagnoses showed that SS diagnosed
6/66 as having ENL and MJ 4/66. They only agreed on one ENL
diagnosis.
Patients at risk of developing T1R and ENL
A sub group of patients at risk of developing T1R was identified.
This excluded patients with ENL and the patients with no
significant lesion (NSL). Patients with ENL were excluded because
they were very unlikely to have both T1R and ENL together at
baseline. Patients with NSL were excluded in this analysis because
the comparison involved a histological comparison and their
biopsy showed so little inflammation that assessing the histological
features of reaction was not possible. Similarly the group at risk of
developing ENL included LL cases plus any BL cases in ENL at
time of leprosy diagnosis. LL cases with no ENL at time of
diagnosis were therefore included in both groups. The NSL group
was excluded from both groups.
Ethical considerations
No financial incentives were given to participants. However,
travel expenses were refunded on occasion and where relevant,
lost earnings of daily labourers compensated. The study adhered
to the International Ethical Guidelines for Biomedical Research
Involving Human Subjects [16]. Permission for the study was
obtained from the Indian Council of Medical Research and the
Research Ethics Committee of the Central JALMA Institute for
Leprosy in Agra gave ethical approval. Written consent was
obtained from individual study subjects before inclusion in the
study, using a standard consent form.
Results
Diagnosis of leprosy
Three hundred and three patients were recruited and 299 had
biopsies that were adequate for examination. Four biopsies were
too small or too superficial with inadequate dermis. Table 1
compares the initial clinical classification which was made against
the histological diagnosis. BT was the main clinical diagnosis,
comprising 59.5% of the patients, but 41% were reclassified after
histological diagnosis: 24 (13%) to BL, two to LL and 32 and 15 to
indeterminate and NSL respectively. Patients in the BL group
were re-classified after histological diagnosis, with 17 going to BT,
nine to LL and two and three to indeterminate and NSL
respectively. The LL group had the highest rate of revised
diagnoses with only 17 cases being diagnosed and confirmed
(54%). Eleven (35%) cases were reclassified to BL, two to BT 6%
and one to Indeterminate. Two BT and nine BL cases were re-
assigned to the LL category. The PN category encompassed the
whole spectrum. Although the PN cases had no apparent skin
lesions, histological evidence of leprosy was found in 9/13 skin
biopsies (one BT, three BL and five indeterminate). Assessing the
agreement between diagnoses was calculated as the number of
positive assessments with agreement as a percentage of the total
number of positive assessments for BT 68.6%, BL 54.2% and LL
57.6%.
Indeterminate/resolved leprosy
Four histological categories were recognised for this group (see
above) so that patients whose leprosy was resolving could be
identified. Sixty one (20.4%) patients had a histological diagnosis
of indeterminate or NSL seen on biopsy. Thirty two biopsies
showed signs of indeterminate leprosy, with the potential to either
progress or heal. Eight biopsies were classed as indeterminate/
resolved, indicating that early leprosy had been present and was
now healing. In 12 biopsies there was no evidence of leprosy. Ten
biopsies were classed as NSL/resolved indicating that a lesion had
been present but was resolving (Table 2). Thus 20.4% of this
cohort of MB leprosy patients had skin biopsies with only minimal
inflammation and in half of these cases there was evidence of
resolution. Clinically these patients had been classified: 47 as BT,
four as BL, one as LL, four as BT (PN) and five as BL (PN). Table 3
shows the clinical signs of leprosy in this group which showed both
significant numbers of skin lesions, ranging from 23.2 (mean) in the
indeterminate group to 16.5 in the NSL/resolved group; and
significant numbers of thickened nerves, ranging from 4.4 (mean)
in the indeterminate group to 2.75 in the NSL group. One patient
had tender nerves. These clinical signs could also be consistent
with active or recently active leprosy. Four patients developed NFI
or reaction (one motor NFI, one neuritis, two sensory NFI) during
follow-up.
Diagnosis of reactions
Type 1 and Type 2 reactions were diagnosed clinically and the
diagnosis reviewed on the database by WvB and DNL. Reactions
were also diagnosed histologically. Of the cohort, 265 patients
were at risk of developing T1R and 43%, 39% and 9% of the
clinically diagnosed BT, BL and LL patients being diagnosed by
the histopathologist as having a T1R in their baseline biopsy. The
histopathologist also rated his diagnostic certainty for a T1R. A
T1R was diagnosed definitely in 96 cases and also in a further 22
biopsies of which 17 were rated probable and six possible T1R.
Table 4 compares the clinical and histological diagnoses of T1R,
differentiating between clinical reactions with skin only, nerve only
and nerve plus skin involvement. We found substantial disparity
between clinical and histological diagnoses of reactions (Table 4).
Clinicians diagnosed reactions in 96 patients (36 skin only, 41
nerve only and 19 skin and nerve). Reactions were diagnosed
histologically in 113 patients (26 skin only, 14 nerve only and 13
skin and nerve). The skin comparisons are the most useful here
since all patients had a skin biopsy but only a subset of patients had
a nerve biopsy. For 109 patients there was clinical and histological
agreement of no reaction and agreement on 53 in reaction. There
were 60 patients with a histological diagnosis of T1R but no
clinical diagnosis and 43 with a clinical diagnosis but not a
Table 1. Comparison of clinical diagnoses and histological
skin biopsy diagnoses at registration.
Skin Biopsy Diagnosis
Clinical Diagnosis BT* BL** LL{ Ind{ NSL1 Total
BT 105 24 2 32 15 178
BBI 2 2 0 0 0 4
BL 18 42 9 1 3 73
LL 2 11 17 1 0 31
PN# 1 3 0 5 4 13
Total 128 82 28 39 22 299
*Borderline tuberculoid leprosy;
**Borderline lepromatous leprosy;
{Lepromatous leprosy;
{Indeterminate leprosy;
1No significant lesion;
IBorderline borderline leprosy;
#Pure Neural leprosy.
doi:10.1371/journal.pntd.0001702.t001
Leprosy Diagnoses: Clinical and Histological
www.plosntds.org 4 June 2012 | Volume 6 | Issue 6 | e1702
histological. Using histological diagnosis as a gold standard, the
sensitivity of clinical diagnosis is 34.5% and the specificity 89.4%.
One hundred and thirteen patients had a clinical diagnosis of BT
leprosy and 49 had T1R diagnosed (17 skin only, 26 nerve only,
six skin and nerve); T1R was diagnosed histologically in 69
patients (55 skin only, 12 nerve only and five skin and nerve). The
sensitivity of clinical diagnosis is 53.1% and the sensitivity is
61.9%. Sixty seven patients had BL leprosy and 36 had a clinical
diagnosis of T1R (15 skin only, 11 nerve only and 10 skin and
nerve). Histological diagnoses were made in 31 patients giving
clinical diagnosis a sensitivity of 61.1% and a specificity of 71.0%.
The clinical information on patients with a histological reaction
diagnosis was explored to see whether the skin diagnosis was a
marker for pathology elsewhere. Seventeen patients had evidence
of an immune mediated process going on elsewhere. Of the seven
BL cases, six had new sensory NFI and one had ENL; of the 10 BT
cases, five had sensory NFI, three both sensory and motor NFI,
and two had other processes (one motor NFI, one ENL). There
were 44 patients who had a clinical diagnosis of T1R and no
evidence of ongoing nerve damage.
The hypothesis that these reaction diagnoses might be
indicators for a reaction about to happen was tested by looking
at the subsequent reaction history of these patients. There were 74
patients in this group, who had been diagnosed with a T1R
histologically but not clinically. Of these, 30 had a reaction during
follow-up and in 15 cases they had a T1R diagnosed both
clinically and histologically. These reactions were spread out over
the follow-up period but with a peak in the first three months of
follow-up when six T1Rs occurred. It is therefore possible that
reactions are being pre-diagnosed by the pathologist but only in a
small number of patients.
ENL
There were 28 patients with LL who were at risk of ENL. ENL
was diagnosed clinically in two LL patients at entry to the study,
while 13 patients had histological evidence of ENL on their skin
biopsy taken at baseline (Table 5). Two patients with BL leprosy
were also diagnosed with ENL.
The certainty of the histological diagnosis of ENL was nine
definite, four probable and three possible. Using histological
diagnosis as a gold standard, this gives clinical diagnosis a
sensitivity of 15.4% and a specificity of 100%. Patients (LL and BL
types) had single and multiple clinical episodes of ENL. Fourteen
patients had 24 episodes of ENL, five occurred at baseline as single
events, and seven patients had multiple episodes in the two year
follow up. We have no data about episodes of ENL after the close
of the two year follow-up. Only two of the 12 patients diagnosed
with histological but not clinical ENL at baseline subsequently
developed ENL.
Discussion
The key finding from this cohort study is that reactions are more
frequent than is clinically evident. We have also shown that leprosy
manifests in a range of clinical and histological pathologies, and
that there are significant numbers of patients both with
indeterminate disease and with healing and resolving disease at
the site of the biopsy. Patients were carefully evaluated at
Table 2. Categories of indeterminate leprosy found on skin biopsy examination.
Indeterminate, NSL* and resolved status
Final Classification (Clinical+histopathology) Ind** Ind/Res{ NSL NSL/Res Total
BL{ 1 0 0 1 2
BL(PN1) 1 1 1 2 5
BTI 27 6 10 7 50
BT(PN) 2 1 1 0 4
Total 31 8 12 10 61
*No significant lesion;
**Indeterminate;
{Resolved;
{Borderline lepromatous leprosy;
1Pure Neural;
IBorderline tuberculoid leprosy.
doi:10.1371/journal.pntd.0001702.t002
Table 3. Clinical signs of leprosy in the indeterminate group.
No. of skin lesions (range) Enlarged nerves (range) Nerve tenderness (range) Paraesthesiae (range)
Ind* (N = 31) 23.2 (0–100) 4.4 (0–12) 0.06 (0–1) 0.55 (0–6)
Ind/Res** (N = 8) 16.5 (0–65) 6.75 (2–12) 0 (0–0) 2.25 (0–8)
NSL{ (N = 12) 23.3 (0–100) 2.75 (0–10) 0 (0–0) 0.58 (0–4)
NSL/Res (N = 10) 17.2 (0–73) 3.9 (0–11) 0 (0–0) 2.3 (0–10)
*Indeterminate;
**Resolved;
{No significant lesion.
doi:10.1371/journal.pntd.0001702.t003
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recruitment and their diagnoses reviewed after the histological
results were available.
There were significant differences in the diagnosis of T1R by
clinicians and pathologists, with the clinicians diagnosing fewer
T1R. This is surprising and contrasts with a previous piece of work
on the diagnosis of T1R in India when histopathologists diagnosed
fewer T1R than clinicians. [10] T1R can be difficult to diagnose; it
can be difficult to differentiate clinically between BT and BT in
reaction. Histologically, the diagnosis depends on demonstrating
granuloma and dermal oedema and these signs can also be
variable. Clinicians and pathologists were probably looking for
different factors to make the diagnosis of a T1R.. There is
variation between pathologists in the agreement on the diagnosis
of reactions. In this INFIR study we have found marked
differences between the assessments that two pathologists give to
the diagnosis of reactions. [3] In the previous study we found that
finding expression of HLA-DR in the epidermis significantly
increased the rate of histological diagnosis, and staining for this
marker could also be applied to these biopsies. It is also important
to ensure that pathologists involved in clinic-pathological studies
have pre-study training to agree on the evaluation of diagnostic
criteria especially for reactions. Studies should be planned that
involved clinicians and pathologists in a real-time review of leprosy
patients with suspected reactions and their biopsy findings so that
diagnostic criteria are established that link the diagnoses of
clinicians and pathologists more closely. It is also important to
determine whether there are clinical consequences, such as new
nerve impairment for patients with sub-clinical reactions. It may
be that patients with subclinical reactions would benefit from
steroid treatment.
ENL was also diagnosed differently by clinicians and patholo-
gists in this cohort. The finding of ENL in 17% of the skin biopsies
from LL patients and 7% from the BL patients shows that ENL is
a continuing problem. This ENL was being diagnosed at baseline,
whereas one would expect a higher rate of ENL after several
months of treatment. The changes seen in the biopsies here when
the diagnosis of ENL was made were typical, with infiltration of
polymorphs into the lesions and a vasculitis. It can be difficult to
diagnose ENL clinically especially when it is present in a mild
form. Still it is surprising that 80% of the histologically diagnosed
ENL episodes at baseline did not have clinical signs of reaction. It
might be difficult to detect ENL in a newly diagnosed LL case
when the LL skin lesions are active. This study suggests that
subclinical ENL may be important. This finding needs to be
validated in other studies and also with patients at risk of ENL
followed closely to determine the clinical effects of sub clinical
ENL. This highlights the importance of training doctors and
health workers to specifically ask patients with LL and BL type
disease about symptoms of ENL such as new nodular lesions, bone
pain, orchitis and fever. ENL is important to diagnose because it
may cause morbidity to eyes, bones and testes.
These data show that the leprosy WHO classification MB group
is very heterogeneous and comprises patients with all types of
leprosy with the exception of single lesion tuberculoid and so
includes patients with Indeterminate, BT, BB, BL, LL and PN
leprosy. Patients were entered into this cohort when the enrolling
clinician felt certain that the patients had a clinical diagnosis of
MB leprosy. Of the BT patients 80% had no mycobacteria
detectable on either slit skin smear or in their biopsies. The BT
disease seen in these patients is immunologically active and we
have reported elsewhere that staining for cytokines and inflam-
matory markers in these biopsies shows a high level of
immunological activation with abundant production of the pro-
inflammatory cytokines TNFa, iNOS, and TGFb. [3] High rates
of BT leprosy in Indian patients have been reported before.
Moorthy et al [6] found that BT leprosy was clinically diagnosed
in 54% of their cohort but present in 72% of biopsies. It is also
surprising that in a cohort designed to recruit new untreated MB
cases that there should be 17.9% patients with histological
evidence of indeterminate or resolving leprosy. There are several
possible explanations that should be considered, inadequate
biopsies (including those taken from a non-active lesion), self
healing of early lesions and undeclared previous treatment. Early
leprosy lesions often have minimal inflammation and in the
Karonga study in Malawi, NSL inflammation was found in 17% of
biopsies taken from a cohort of 664 patients with suspected
leprosy. [17] The biopsy might also have missed the active
inflammation. In the study of Moorthy et al, indeterminate leprosy
was reported clinically in 3.5% and found histologically in 6.7% of
patients. It may be postulated that this high rate of self healing is
part of a picture of local high endemicity where there is a high rate
of infection with M. leprae and a high self healing rate. There can
be very high rates of local infection in the Indian sub-continent. In
Mumbai, Shetty et al [18] have found local case detection rates of
leprosy as high as 9.42/10,000.
The reclassifications that occurred between the BL and BT
group are not surprising because the skin lesions may appear
similar. Furthermore patients may spontaneously upgrade from a
BL to BT phenotype without having an overt T1R. Conversely,
patients with BT leprosy may be moving silently towards the BL
and even LL phenotypes and this is reflected in the results. We
found 24 patients initially classified as BT whose skin biopsies
showed BL leprosy and two biopsies that showed LL.
There was also significant under-diagnosis of LL disease in this
cohort. Most of the misdiagnoses relating to LL disease were in the
BL group and differentiating between these two types is not always
straightforward. Groenen et al [19] found that adding in a
Table 4. Comparison of clinical and histological diagnoses of
Type 1 Reactions.
Histological diagnosis
Clinical diagnosis T1R* present T1R absent Total
T1R present, +/2nerve
involvement
26+13 = 39
70.9%, 34.5%
10+6= 16
29.1%, 10.5%
55
20.8%
T1R absent, +/2nerve
involvement
60+14 = 74
65.5%
109+27 = 136
89.5%
210
79.2%
113 (42.6%) 152 (57.4%) 265
*Type 1 Reaction.
doi:10.1371/journal.pntd.0001702.t004
Table 5. Erythema Nodosum Leprosum diagnoses.
Skin biopsy diagnosis of ENL*
Clinical Diagnosis of ENL Present Absent Total
Present 2 0 2
Absent 11 17 28
Total 13 17 30
*Erythema Nodosum Leprosum.
NB: This gives sensitivity 1/13 = 0.154 and specificity 1.0. Numbers could be
added to the test, though N is small (Page 12).
doi:10.1371/journal.pntd.0001702.t005
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category of diffuse infiltration and nodules improved the diagnosis
of LL cases in the MB leprosy classification by ensuring that diffuse
infiltration is not overlooked.
This data re-iterates the value of doing skin biopsies in leprosy
especially when reactions are suspected.
One simple lesson from this study is that the MB classification is
useful because these patients have a high rate of leprosy reactions,
and resources and follow-up should be focused on these patients.
The findings from this cohort illustrate how complex diagnosis
and classification of leprosy reactions can be and how important
regular discussion and review of patients and their biopsies
between pathologists and clinicians can be. It is also important that
referral centres should have a ready access to pathologists who are
experienced in leprosy diagnosis and this should be recognised
when planning and funding such centres. It is very important that
both clinicians and pathologists be aware of the local patterns of
presentation and are able to detect changes in these patterns. It
would also be useful to quiz these patients further to establish
whether any of them have received anti-leprosy drugs from
another source such as a private practitioner. It is also important
that there should be teaching and training about classification of
leprosy patients and this is another function of referral centres that
needs to be developed.
This study has shown that leprosy continues to present in a
range of forms and that early self healing disease is present as well
as the more advanced forms. In this report we have focused on the
changes seen in skin biopsies and have found that there is a
significant under-diagnosis of both T1R and ENL, when
comparing clinical diagnosis against histological evidence. This
has important clinical implications for training and service
delivery. Health workers need to be trained to suspect reactions,
robust referral systems for evaluating patients with suspected
reactions need to be developed and programme managers need to
ensure that there are adequate supplies of steroids for the
treatment of reactions in both field stations and referral centres.
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